Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Recruiting now · Not applicable

Conditions studied: Pancreatic Cancer Non-resectable, Tumor Pancreas, Pain Cancer

In brief

Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.

Key facts

Study ID

NCT06160323

Run by

Chinese University of Hong Kong

People needed

94

Starts

2023-11-10

Expected to finish

2028-07-31

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >= 18 years old
• Diagnosed to have inoperable pancreatic cancer
• Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS >= 3
• Karnofsky performance status >= 60
• Planned for EUS examination and/or biopsy of the pancreatic tumor

You may not qualify if…

• Allergy to bupivacaine, or alcohol
• Potentially operable after neoadjuvant therapy
• Expected survival of less than 3 months
• Patient who is already on opioids for pain control
• Previous percutaneous or EUS-guided CGN/ CPN
• Recurrent pancreatic tumors after operation
• Uncorrectable coagulopathy
• Inability or unwillingness to provide informed consent

Where it is running

• Prince of Wales Hospital — Hong Kong, Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.